No description available.

With the advent of fluorescence microscopy and image analysis, quantitative information from images can be extracted and changes in cell morphology can be studied. Microscopy-based morphological profiling assays with multiplexed fluorescent dyes, like Cell Painting, can be used for this purpose. It has been shown that morphological profiles can be used to train AI models to classify images into different biological mechanisms. Hence, the goal of this project was to study the possibilities for Deep Learning models and Convolutional Neural Networks to distinguish between different classes of kinase inhibitors based on their morphological profiles. Three different Convolutional Neural Network architectures were used: ResNet50, MobileNetV2, and VGG16. They were trained with two different inputs and two different optimisers: Adam and SGD. Also, a comparison between the performances with and without Transfer Learning through ImageNet weights was executed. The results indicate that MobileNetV2 with Adam as an optimiser performed the best, with a micro average of 0.93 and higher ROC areas compared to the other models. The study also highlighted the importance of utilizing Transfer Learning.

La nécroptose est une mort cellulaire régulée impliquée dans les pathologies inflammatoires, ischémiques et dégénératives. RIPK1 serait une cible thérapeutique intéressante car son activité kinase serait à l’origine de leur initiation ou aggravation. Nous avons caractérisé les effets biologiques de deux nouveaux inhibiteurs de RIPK1. La sibiriline protège les souris d’une hépatite autoimmune et 6E11 protège les cellules endothéliales de l’aorte de la mort par ischémie froide/réoxygénation, suggérant des propriétés intéressantes pour ces inhibiteurs. Ces composés diffèrent par leur mode d’action, d’interaction et de sélectivité, et restent à optimiser en vue d’une utilisation thérapeutique. / Necroptosis is a regulated cell death pathway involved in inflammatory, ischemic or degenerative diseases. RIPK1 would be an interesting therapeutic target since its kinase activity is probably responsible of their initiation or aggravation. We have characterized the biological effects of two new RIPK1 inhibitors. Sibirilin protects mice from autoimmune hepatitis and 6E11 protects endothelial aortic cells from death due to cold ischemia/reoxygenation, suggesting interesting properties for these inhibitors. These compounds differ in their mode of action, interaction and selectivity, and still need to be optimized for therapeutic use.

No description available.

BACKGROUND: Netarsudil, a Rho kinase and norepinephrine transport (NET) inhibitor, is a new FDA approved drug used for decreasing raised intraocular pressure (IOP) in ocular hypertensive and primary open-angle glaucoma (POAG) patients. Previous studies reported that netarsudil increased outflow facility and lowered IOP by increasing active outflow areas around the circumference of the eye and dilating the episcleral veins (ESV; Kiel and Kopczynski, 2015; Ren et al., 2016). However, the mechanisms by which netarsudil increases outflow facility have not yet been fully elucidated. Moreover, the effects of netarsudil on the inner wall (IW) endothelium I-pores and B-pores of the Schlemm’s canal (SC) have also not been investigated yet. AIM: The goal was to determine if netarsudil-treatment increased the effective filtration areas (EFA) by increasing pore density in both high- and non-flow type areas, compared to untreated control eyes. METHODS: In this study, the effects of netarsudil on the pore densities on IW of SC were investigated by serial block-face scanning electron microscopy (SBF-SEM). Two pairs of eyes were perfused with green fluorescent tracers in order to determine the outflow pattern prior to treatment. Then, one eye of each pair was perfused with netarsudil, while the fellow eye of each pair was perfused with vehicle solution. All eyes were then perfused with red fluorescent tracers in order to determine the outflow pattern once they were treated with netarsudil. Both pairs of eyes were perfused and fixed at 15 mmHg. Global imaging was performed for all eyes to visualize high- and non- flow areas in the trabecular meshwork (TM) and ESV’s. A SBF-SEM was used to image eight wedges of tissue including the IW of SC and TM (high- and non-flow areas from four eyes) for a total of 16,378 images. The study analyzed the percentage of pore-types (GV-associated I-pores, Non-GV associated I-pores, B-pores), the median pore spans, the GV-associated I-pore locations, and the pore densities (per IW nuclei and IW area) between the equivalent control and netarsudil-treated flow areas. RESULTS: In global images, an increase in high-flow areas were observed in netarsudil-treated eyes due to recruitment from low-flow and non-flow areas. A greater percentage of GV-associated I-pores, B-pores, and total pores were found in high-flow in contrast to non-flow areas in both control and netarsudil-treated eyes (all P ≤ 0.05). However, the percentage of GV-associated I-pores in non-flow areas were significantly greater in treated compared to control eyes (P ≤ 0.05). Qualitative observations from two pairs of eyes showed a trend of greater I-pore, B-pore, and total pore density/per IW nucleus and density/per IW surface area in high-flow in contrast to non-flow areas for both treated and control eyes. No difference in I-pore, B-pore, and total pore density/per IW nucleus and density /per IW surface area were observed in equivalent flow-type areas when comparing control and netarsudil-treated eyes. In addition, there was a significant greater percentage of I-pores located on the side of GVs than the top of GVs in all cases (P ≤ 0.05). CONCLUSIONS: Netarsudil increased high-flow areas. A greater pore density was found in high-flow in contrast to non-flow areas. Netarsudil also significantly increased the proportion of GV-associated I-pores in non-flow areas when compared to control eyes. Our results suggests that one mechanism of netarsudil increasing outflow facility is acting through recruiting the high-flow areas around the circumference of the eye, which is associated with higher pore density and increasing the proportion of GV-associated I-pores in non-flow areas.

Background: Treatment options for poorly differentiated (PDTC) and anaplastic (ATC) thyroid carcinoma are unsatisfactory and prognosis is generally poor. Lenvatinib (LEN), a multi-tyrosine kinase inhibitor targeting fibroblast growth factor receptors (FGFR) 1-4 is approved for advanced radioiodine refractory thyroid carcinoma, but response to single agent is poor in ATC. Recent reports of combining LEN with PD-1 inhibitor pembrolizumab (PEM) are promising. Materials and Methods: Primary ATC (n=93) and PDTC (n=47) tissue samples diagnosed 1997-2019 at five German tertiary care centers were assessed for PD-L1 expression by immunohistochemistry using Tumor Proportion Score (TPS). FGFR 1-4 mRNA was quantified in 31 ATC and 14 PDTC with RNAscope in-situ hybridization. Normal thyroid tissue (NT) and papillary thyroid carcinoma (PTC) served as controls. Disease specific survival (DSS) was the primary outcome variable. Results: PD-L1 TPS≥50% was observed in 42% of ATC and 26% of PDTC specimens. Mean PD-L1 expression was significantly higher in ATC (TPS 30%) than in PDTC (5%; p<0.01) and NT (0%, p<0.001). 53% of PDTC samples had PD-L1 expression ≤5%. FGFR mRNA expression was generally low in all samples but combined FGFR1-4 expression was significantly higher in PDTC and ATC compared to NT (each p<0.001). No impact of PD-L1 and FGFR 1-4 expression was observed on DSS. Conclusion: High tumoral expression of PD-L1 in a large proportion of ATCs and a subgroup of PDTCs provides a rationale for immune checkpoint inhibition. FGFR expression is low thyroid tumor cells. The clinically observed synergism of PEM with LEN may be caused by immune modulation.

No description available.

付記する学位プログラム名: デザイン学大学院連携プログラム / 京都大学 / 新制・課程博士 / 博士(情報学) / 甲第24031号 / 情博第787号 / 新制||情||134(附属図書館) / 京都大学大学院情報学研究科知能情報学専攻 / (主査)教授 阿久津 達也, 教授 山本 章博, 教授 鹿島 久嗣 / 学位規則第4条第1項該当 / Doctor of Informatics / Kyoto University / DFAM

No description available.

A leucemia mielóide crônica (LMC) é uma doença mieloproliferativa clonal caracterizada pela presença do cromossomo Philadelphia e o oncogene BCR-ABL1. Este oncogene codifica a oncoproteína Bcr-Abl com atividade tirosina-quinase constitutiva. A proteína Bcr-Abl é responsável pela resistência das células leucêmicas a apoptose. Atualmente, os pacientes com LMC são tratados com os inibidores de tirosina-quinase - mesilato de imatinibe, dasatinibe e nilotinibe. Apesar de o tratamento ser eficiente, pacientes em fases avançadas e mesmo na fase crônica da doença, apresentam resistência à terapia. Desta forma, novos fármacos devem ser investigados para melhorar o tratamento da LMC. As L-aminoácido oxidases (LAAOs) têm sido descritas como substâncias citotóxicas e indutoras de apoptose. Assim, o principal objetivo do presente estudo foi investigar o potencial antitumoral da LAAO isolada da serpente Calloselasma rhodostoma (CR-LAAO) nas células Bcr-Abl positivas. Avaliou-se a citotoxicidade da CR-LAAO nas linhagens HL-60 (linhagem Bcr-Abl negativa), HL-60.Bcr-Abl, K562 e KCL22 (linhagens Bcr-Abl positivas) e nas células mononucleares (MNC) de sangue periférico de indivíduos saudáveis, na presença ou ausência da catalase. Para investigar os mecanismos da ação citotóxica da CR-LAAO, realizou-se os ensaios de indução de apoptose por meio da quantificação das percentagens de núcleos hipodiplóides e anexina V-FITC, nas linhagens celulares e nas células MNC de indivíduos saudáveis e pacientes com LMC. Avaliou-se também os níveis de expressão das caspases 3, 8 e 9, o potencial de membrana mitocondrial, danos no DNA e o efeito apoptótico da toxina combinada com os inibidores de tirosina-quinase nas linhagens Bcr-Abl positivas. Além disso, investigamos se a CR-LAAO foi capaz de modular a expressão dos apoptomiRs miR-15a, miR-16, miR-145, miR-26a, hsa-let-7d, miR-142-3p, miR-29c, miR-146a, miR-21, miR-130a e miR-130b, assim como das proteínas pro- e anti-apoptóticas Bak, Bax, Bid, Bim, A1, Bcl-2, c-Flip, Ciap-2 e Mcl-1 nas linhagens Bcr-Abl positivas. Nossos resultados mostraram que o efeito citotóxico da CR-LAAO foi mais potente nas linhagens Bcr-Abl positivas em relação às células MNC de indivíduos saudáveis, e está associado ao peróxido de hidrogênio produzido durante a reação enzimática da CR-LAAO. Demonstrou-se também que a CR-LAAO induziu apoptose nas linhagens Bcr-Abl postivas testadas e nas células MNC de pacientes com LMC na fase crônica da doença. Em todas as linhagens celulares detectou-se danos no DNA, perda do potencial de membrana e ativação das caspases 3, 8 e 9. A percentagem de apoptose aumentou quando as células HL-60.Bcr-Abl foram tratadas com a CR-LAAO combinada com os inibidores de tirosina-quinase. A CR-LAAO modulou a expressão dos apoptomiRs miR-15a, miR-16, miR-145, miR-26a, hsa-let-7d, miR-142-3p, miR-29c, miR-21, miR-130a e miR-130b e de possíveis proteínas alvos nas linhagens Bcr-Abl positivas. Sendo assim, os resultados obtidos sugerem que a CR-LAAO apresenta uma ação antitumoral capaz de destruir as células leucêmicas / Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by the presence of Philadelphia chromosome and BCR-ABL1 oncogene. This oncogene encodes the Bcr-Abl tyrosine kinase (TK) which presents a constitutive activity. The Bcr-Abl is responsible for leukemic cells resistance to apoptosis. The CML patients are currently treated with tyrosine kinase inhibitors (TKI) - imatinib mesylate, dasatinib and nilotinib. Although TKI are efficient for CML treatment, patients in advanced phases and even in chronic phase of the disease present resistance to therapy. Thus, potential new drugs must be investigated to improve the CML treatment. The L-amino acid oxidases (LAAOs) have been described as cytotoxic and apoptosis-inducing substances. Here, we investigated the LAAO from Calloselasma rhodostoma (CR-LAAO) antitumoral potential against Bcr-Abl positive cells. We evaluated the CR-LAAO cytotoxic effect against HL-60 (Bcr-Abl negative cell line), HL-60.Bcr-Abl, K562, KCL22 (Bcr-Abl positive cell lines) and the peripheral blood mononuclear cells (PBMC) from healthy subjects, in the presence or absence of catalase. To investigate the mechanisms underlying the CR-LAAO cytotoxic action, we performed the apoptosis induction assays through the hypodiploid nuclei and annexin-V quantification in the cell lines and PBMC from healthy subjects and CML patients. We also evaluated the levels of caspases 3, 8 and 9 expression, the mitochondrial membrane potential, DNA damage and the apoptotic effect of CR-LAAO combined with TKI on Bcr-Abl positive cells. In addition we investigated if CR-LAAO was capable of modulating the apoptomiRs miR-15a, miR-16, miR-29c, hsa-let-7d, miR-145, miR-146a, miR-21, miR-130a, miR-130b, miR-142-3p and miR-26a, the pro- and anti-apoptotic proteins (Bak, Bax, Bid, Bim, A1, Bcl-2, c-Flip, Ciap-2 and Mcl-1 expression in HL-60, HL-60.Bcr-Abl, K562 and KCL22 cells. Our results showed that the CR-LAAO cytotoxic effect was more potent in Bcr-Abl positive cell lines than in PBMC from healthy subjects and it is linked to hydrogen peroxide produced during the enzymatic action of CR-LAAO. It was also demonstrated that CR-LAAO was capable of inducing apoptosis in Bcr-Abl positive cell lines and CML patient\'s cells in chronic phase of the disease. In all tested cell lines, the loss of mitochondrial membrane potential, DNA damage and caspases 3, 8 and 9 activation were detected. The apoptosis percentage was improved when HL-60.Bcr-Abl cells were treated with CR-LAAO combined with TKI. The CR-LAAO modulated the apoptomiRs miR-15a, miR-16, miR-145, miR-26a, hsa-let-7d, miR-142-3p, miR-29c, miR-21, miR-130a and miR-130b expression as well the predict target proteins levels on Bcr-Abl positive cells. Thus, our results suggest that CR-LAAO presents an antitumoral action capable of destroying the CML cells.